An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data

Medical Care

Volumn 53, Issue 7, 2015, Pages e49-e57

  Whyte, Joanna L ^a   Engel Nitz, Nicole M ^b   Teitelbaum, April ^b,c   Gomez Rey, Gabriel ^b   Kallich, Joel D ^d  

^a CSL Behring LLC   (United States)

^b Health Economics and Outcomes Research   (United States)

^c Heme Onc Associates and AHT BioPharma Advisory Services   (United States)

^d AMGEN INC   (United States)

Author keywords

administrative claims; metastatic cancer; validation

Indexed keywords

ADULT; ARTICLE; BREAST METASTASIS; CANCER PATIENT; CLASSIFICATION ALGORITHM; FEMALE; HEALTH INSURANCE; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; ALGORITHM; BREAST TUMOR; COLORECTAL TUMOR; EVALUATION STUDY; INSURANCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; UNITED STATES;

AGED; ALGORITHMS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84933673026     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318289c3fb     Document Type: Article

References (41)

1. Pearson ML, Ganz PA, McGuigan K, et al. The case identification challenge in measuring quality of cancer care. J Clin Oncol. 2002;20:4353-4360.
2. Leung KM, Hasan AG, Rees KS, et al. Patients with newly diagnosed carcinoma of the breast: validation of a claim-based identification algorithm. J Clin Epidemiol. 1999;52:57-64.
3. Baldi I, Vicari P, Di Cuonzo D, et al. A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. J Clin Epidemiol. 2008;61:373-379.
4. Eichler AF, Lamont EB. Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol. 2009;95: 427-431.
5. Meguerditchian AN, Stewart A, Roistacher J, et al. Claims data linked to hospital registry data enhance evaluation of the quality of care in breast cancer. J Surg Oncol. 2010;101:593-599.
6. Schulman K, Berenson K, DeSouza J. A Checklist for Population Selection in Oncology Outcomes Research Using Secondary Data Sources. Baltimore, MD: International Society of Pharmacoeconomic and Outcomes Research (ISPOR); 2011.
7. Friedlin J, Overhage M, Al-Haddad MA, et al. Comparing methods for identifying pancreatic cancer patients using electronic data. AMIA Annu Sump Proc. 2010;13:237-241.
8. Nattinger AB, Laud PW, Bajorunaite R, et al. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39:1733-1749.
9. Gold HT, Do HT. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data. Health Serv Res. 2007;42: 2056-2069.
10. Koroukian SM, Cooper GS, Rimm AA. Ability of Medicaid claims data to identify incident cases of breast cancer in the Ohio Medicaid population. Health Serv Res. 2003;38:947-960.
11. Du XL, Key CR, Dickie L, et al. External validation of Medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44:124-131.
12. Lamont EB, Herndon JE, Weeks JC, et al. Criterion validity of Medicare chemotherpay cliams in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005;97:1080-1083.
13. Cooper GS, Yuan Z, Stange KC, et al. The utility of Medicare claims data for measuring cancer stage. Med Care. 1999;37:706-711.
14. Rolnick SJ, Hart G, Barton MB, et al. Comparing breast cancer case identification using HMO computerized diagnostic data and SEER data. Am J Manag Care. 2004;10:257-262.
15. Solin LJ, MacPherson S, Schultz DJ, et al. Evaluation of an algorithm to identify women with carcinoma of the breast. J Med Syst. 1997;21:189-199.
16. Ramsey SD, Scoggins JF, Blough DK, et al. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009;15:659-668.
17. Smith TJ, Hillner BE. Bending the cost curve in cancer. N Engl J Med. 2011;364:2060-2065.
18. Chastek B, Harley D, Kallich JD, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8:75s-80s.
19. Mariotto AB. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2012;103:117-128.
20. Cancer Research UK. Web site 2012 [cited 2012 Aug 1]. Available at: http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions. Accessed 1 August 2012.
21. National Comprehensive Cancer Network (NCCN). NCCN Guidelines. Available at: http://www.nccn.org/professionals/physician-gls/f-guide lines.asp. Accessed 1 August 2012.
22. Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. BMC Health Serv Res. 2011;11:305. DOI: 10.1186/1472-6963-11-305.
23. Health Insurance Portability and Accountability Act of 1996. In: 104th Congress and US Department of Health and Human Services, ed., Public law 104-191. Available at: http:/www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed 1 August 2012.
24. O'Conner J, Khan JD, Woo RK. Inventors; United States, assignee. Impact Intelligence Oncology Management. 2010.
25. Comorbidity Software [computer program]. Agency for Healthcare Research and Quality (AHRQ); 2009.
26. Elixhauser A, Steiner C, Harris D, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
27. Weycker D, Edelsberg J, Kartashov A, et al. Risk and health care costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. J Clin Oncol. 2011;29(suppl 15):1050.
28. Florkowski CM. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev. 2008;29(suppl 1):S83-S87.
29. Fisher L, Van Belle G. Biostatistics: A Methodology for the Heatlh Sciences. New York: John Wiley & Sons Inc.; 1993.
30. Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastimor pegfilgrastim associated with 3-4 week chemotherapy regimens in comunity oncology practices. J Manag Care Pharm. 2007;13:337-348.
31. Shapiro DE. The interpretation of diagnostic tests. Stat Methods Med Res. 1999;8:113-134.
32. Gustafson P. Measurement Error and Misclassification in Statistics and Epidemiology: Impacts and Bayesian Adjustments. Boca Raton, Florida: Chapman and Hall/CRC Press; 2003.
33. Lynch C. A Review of the Definition for Multiple Primary Cancers in the United States. Workshop Proceedings From December 4-6, 2002, in Princeton, New Jersey. Springfield (IL): North American Association of Central Cancer Registries; 2003.
34. Ozsoy O, Fioretta G, Ares C, et al. Incidental detection of synchronous primary tumours during staging workup for prostate cancer. Swiss Med Wkly. 2010;140:223-236.
35. Rostad H, Strand TE, Naalsund A, et al. Resected synchronous primary malignant lung tumors: a population-based study. Ann Thorac Surg. 2008;85:204-209.
36. McGuirt WF. Panendoscopy as a screening examination for simultaneous primary tumors in head and neck cancer: a prospective sequential study and review of the literature. Laryngoscope. 1982;92:569-576.
37. Beisland C, Talleraas O, Bakke A, et al. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int. 2006;97:698-702.
38. van Niekerk CC, Vooijs GP, Bulten J, et al. Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor. Mod Pathol. 2007;20:384-388.
39. Wilt TJ, Shamliyan T, Taylor B, et al. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
40. Nordstrom B, Whyte JL, Stolar M, et al. Development of Algorithms to Identify Metastatic Cancer in Claims Data, using Oncology EMR Data. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2011.
41. Nordstrom B, Whyte JL, Stolar M, et al. Identification of metastatic cancer in claims data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2): 21-28.